CLL: Study of interest - Myvax while in watchful waiting

[Guest guest]

Greetings,

Within is a press release about the new vaccine study for CLL, along with a

protocol outline and a link to details.

~ Karl

=

Genitope Corporation Initiates Clinical Trial to Evaluate MyVax®

Personalized Immunotherapy in the Treatment of Chronic Lymphocytic Leukemia

REDWOOD CITY, Calif., Feb. 27 /PRNewswire-FirstCall/ -- Genitope Corporation

(Nasdaq: GTOP) today announced the initiation of a clinical trial to

evaluate the use of MyVax® personalized immunotherapy to treat Chronic

Lymphocytic Leukemia (CLL), a type of cancer affecting the blood and bone

marrow. MyVax® personalized immunotherapy is based on the unique genetic

makeup of a patient's own tumor, and is designed to activate the patient's

immune system to fight cancer.

" Active immunotherapy, sometimes called a cancer vaccine, has shown

considerable promise in treating non-Hodgkin's lymphoma, " said Dan W.

Denney, Jr., Ph.D., chief executive officer of Genitope.

" The initiation of this trial marks a key milestone in our efforts to expand

the clinical development of MyVax® personalized immunotherapy beyond

non-Hodgkin's lymphoma in the hope of finding an effective treatment for

CLL. "

Nine leading North American cancer centers will begin registering

approximately 70 patients in a Phase I/II clinical trial to investigate

MyVax® personalized immunotherapy for treating CLL. Men and women 18 years

of age or older who have been diagnosed with CLL Rai stage 0, I and II, and

who are untreated may be eligible for the study. Eligible patients will

receive a series of 16 injections of his or her custom-made immunotherapy

over a 52-week period.

" B-cell malignancies are good candidates for active immunotherapy. Unlike

many other types of cancer, B-cell leukemias and lymphomas each have unique

proteins that can distinguish them from one another and from normal cells.

MyVax® personalized immunotherapy will help the body target this unique

protein on the cancer cells, while sparing healthy cells, " said the study's

lead investigator, Tom Kipps, M.D., Ph.D., Professor of Medicine, Head of

the Hematologic Malignancies Program and Deputy Director for Research at the

s Cancer Center at University of California, San Diego.

" The goals of this Phase I/II study are to determine whether MyVax®

personalized immunotherapy can induce anti-tumor immune responses that can

eradicate or block the progression of leukemia and to ascertain the

tolerability of this innovative approach as a therapy for CLL. "

" The results of early clinical trials at Stanford University Medical Center

suggest that personalized active immunotherapy may induce long-term

remission and improve survival in NHL patients, which leads us to believe

this treatment method may be useful in other B-cell malignancies, " said

Furman, M.D., head of CLL and Waldenstrom's Macroglobulinemia

program at Weill Medical College of Cornell University in New York.

CLL is a type of cancer in which the bone marrow makes too many lymphocytes,

a type of white blood cell. It is characterized by an uncontrolled

accumulation of large numbers of lymphocytes in the blood, bone marrow,

lymph nodes and other organs. CLL, which is currently incurable, affects

approximately 70,000 patients in the U.S.

For more information about the trial and a complete list of open trial

sites, patients can call Genitope Corporation at 866-GENITOPE or visit the

company's Web site at http://www.genitope.com.

Genitope Protocol 2005-11: Phase 1/2 Study to Evaluate the Feasibility and

Tolerability of Treatment of Previously Untreated B-Cell Chronic Lymphocytic

Leukemia (B-CLL) Patients with Recombinant Idiotype Conjugated to KLH

(Id-KLH) Administered with GM-CSF.

Protocol outline: Eligible patients will provide a blood sample or tissue

sample from which their personalized immunotherapy will be made. Manufacture

of Personalized Immunotherapy may take up to 8 months. Patients' disease

activity will be observed while their personalized immunotherapy is being

made. " Watchful waiting " is the typical standard of care for patients who

are eligible for this study. Once the personalized immunotherapy is

produced, a series of 16 immunizations with Id-KLH plus GM-CSF will be given

over a 1-year time period. The immunizations will be followed by a 1-year

observation period during which study visits will occur every 3 months.

After that, patients or their treating physicians will be contacted every 6

months to collect information about subsequent anti-leukemia therapy and

survival.

For details see: http://www.genitope.com/tr2011.html

About Genitope Corporation

Genitope Corporation (Redwood City, Calif.) is a biotechnology company

focused on the research and development of novel immunotherapies for the

treatment of cancer. Genitope Corporation's lead product candidate, MyVax®

personalized immunotherapy, is a patient-specific active immunotherapy based

on the unique genetic makeup of a patient's tumor and is designed to

activate the patient's immune system to identify and attack cancer cells.

For more information on the company, please log on to

http://www.genitope.com.

Forward Looking Statements

This news release contains " forward-looking statements. " For this purpose,

any statements contained in this press release that are not statements of

historical fact may be deemed forward-looking statements, including

statements regarding the potential efficacy of MyVax® personalized

immunotherapy for the treatment of NHL and CLL and the anticipated timing,

scope and potential outcome of Genitope Corporation's Phase I/II clinical

trial of MyVax® personalized immunotherapy for the treatment of CLL. Words

such as " believes, " " anticipates, " " plans, " " expects, " " will, " " intends " and

similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause Genitope

Corporation's results to differ materially from those indicated by these

forward-looking statements, including, without limitation, risks related to

the progress, timing and results of Genitope Corporation's clinical trials,

risks relating to the manufacturing of MyVax® and other risks detailed in

Genitope Corporation's filings with the Securities and Exchange Commission,

including under the heading " Risk Factors " in the prospectus supplement and

accompanying prospectus filed by Genitope Corporation with the Securities

and Exchange Commission on February 8, 2006. You are cautioned not to place

undue reliance on these forward-looking statements, which speak only as of

the date of this press release. Genitope Corporation undertakes no

obligation to revise or update any forward-looking statements to reflect

events or circumstances after the date hereof.

Media Contact:

Waters / Jackie Quintanilla

P: 310-593-3443 / 310-962-2005,

lisa.waters@...

jacqueline.quintanilla@...

Investor Contact:

Vuko

Chief Financial Officer, Genitope Corporation,

P: 650-482-2000

IR@...

Donna Shu

Manager of Advocacy Development

Genitope Corporation